Greg Riely, medical oncologist from MSKCC, discusses the
controversial question of whether patients should continue on an
oral EGFR tyrosine kinase inhibitor after progression.
About the Podcast
Expert oncologists provide brief, distilled summaries of the most central issues in cancer management and emerging approaches for patients and caregivers. The Global Resource for Advancing Cancer Education (GRACE) is committed to providing the knowledge that will help enable the general public to be informed participants in their own care. Visit cancerGRACE.org for more info.